DUXAP9 and non-small cell lung carcinoma: Moreover, in a set of 216 NSCLC patients in the Sun Yat‐sen University Cancer Center (SYSUCC) cohort (Table S1) for whom overall survival data were available, patients with high DUXAP9‐206 expression (SI >3) had shorter overall survival times than those with low DUXAP9‐206 (SI ≤3) expression suggesting that DUXAP9‐206 level might be indicative of the prognosis of NSCLC (Figure 1D‐F).